FTO and cancer: Recent reports have shown that FTO, which is expressed at low levels in patient-derived cells, hinders the ability of cancer stem cells in CRC through its demethylase activity and increases m6Am levels in mRNA, resulting in enhanced tumorigenicity and chemoresistance in vivo [175] (Table 3).